This non-interventional study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the local label will be followed for 12 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01663506?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
